Biotech News

iSpecimen Reports Third Quarter 2022 Financial and Operating Results

iSpecimen (ISPC)iSpecimen2022-11-08 07:00 ESTEarnings

- Reported Revenue of $2.6 Million, Comprised Of A Record 88% Non-COVID Revenue -

LEXINGTON, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=sBXaxweR5o98LF9y3CdOPAUl2cIrgnsQNACVpjomM-0PtlZcVFrMKh46PvCwh27g7Vfo-9uvOCNOPBOmVeN6Ng==" rel="nofollow"...

Related news

ISPCiSpecimen2023-11-02 07:30 EST

iSpecimen Reports Third Quarter 2023 Financial and Operating Results

ISPCiSpecimen2023-08-02 07:00 EST

iSpecimen Reports Second Quarter 2023 Financial and Operating Results

View all latest news

iSpecimen

iSpecimen is a healthcare data and biospecimen marketplace company that connects researchers with human biospecimens and related services. Its role is to support research and translational work rather than develop therapies.

Recent company news

ISPCiSpecimen2025-01-16 16:01 EST

iSpecimen Secures Suppliers for COVID-style hMPV Outbreak

ISPCiSpecimen2024-12-20 08:30 EST

iSpecimen Will Serve as a Preferred Provider of Cancer Biospecimens

ISPCiSpecimen2024-12-13 07:30 EST

iSpecimen Reports Positive Results on Next Day Quote Program for Researchers and Providers

ISPCiSpecimen2024-12-12 17:11 EST

iSpecimen Appoints Robert Lim as CEO and Director

ISPCiSpecimen2024-11-08 07:30 EST

iSpecimen Named Top Competitor in $4.4 Billion USD Market

Stock data

Close: 1.69 USD
Market cap: 4.41M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States